Stock Events

Stock Events

Verrica Pharmaceuticals 

$6.26
30
-$0.27-4.13% Friday 20:00
+$0.00+0%Friday 20:00After hours

Statistics

Day High
6.32
Day Low
6.31
52W High
9.82
52W Low
3.28
Volume
1,591
Avg. Volume
-
Mkt Cap
107.54M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-1.26
-0.83
-0.41
0.02
Expected EPS
-0.402
Actual EPS
N/A

Financials

-50.27%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
35.58MRevenue
-17.89MNet Income

Analyst Ratings

12.00Average Price Target
The highest estimate is 12.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VRCA. It's not an investment recommendation.
AMD
6
AMD
Apple
5
AAPL
Realty Income
4
O
Amazon
4
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AnaptysBio
ANAB
Mkt Cap1.88B
AnaptysBio, Inc. focuses on developing antibody-based therapies for dermatological conditions, directly competing with Verrica's dermatology products.
Journey Medical
DERM
Mkt Cap195.22M
Journey Medical Corporation is directly involved in dermatology, marketing products that compete in the same space as Verrica's treatments for skin conditions.
Bausch Health Companies
BHC
Mkt Cap1.83B
Bausch Health Companies Inc. has a broad portfolio in dermatology, offering products that compete with Verrica's skin treatment solutions.
Pfizer
PFE
Mkt Cap138.61B
Pfizer Inc. has a diverse range of healthcare products, including treatments for dermatological conditions, making it a competitor in the dermatology market.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, offers products for skin health, competing in the same market as Verrica.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie Inc. has a strong presence in dermatology with its Humira product and others, competing in the same therapeutic areas as Verrica.
AMGEN
AMGN
Mkt Cap201.93B
Amgen Inc. develops treatments for various conditions, including skin diseases, making it a competitor in the dermatology space.
GSK
GSK
Mkt Cap107.47B
GlaxoSmithKline plc has a portfolio that includes treatments for skin conditions, competing with Verrica's dermatological products.
Merck
MRK
Mkt Cap319.99B
Merck & Co., Inc. offers a range of healthcare products, including treatments for skin conditions, making it a competitor in the dermatology market.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.59B
Regeneron Pharmaceuticals, Inc. is known for its innovative treatments in dermatology, directly competing with Verrica Pharmaceuticals in the development of skin disease treatments.

About

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Show more...
CEO
Dr. Jayson M. Rieger M.B.A., Ph.D.
Employees
76
Country
United States
ISIN
US92511W2070

Listings

XNAS
US
VRCA
STU
DE
1NE0.STU
STU
DE
1NE.STU
MU
DE
1NE0.MU

0 Comments

Share your thoughts

FAQ

What is Verrica Pharmaceuticals stock price today?▼
The current price of VRCA is $6.26 USD — it has decreased by -4.13% in the past 24 hours. Watch Verrica Pharmaceuticals stock price performance more closely on the chart.
What is Verrica Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Verrica Pharmaceuticals stocks are traded under the ticker VRCA.
Is Verrica Pharmaceuticals stock price growing?▼
VRCA stock has risen by +2.04% compared to the previous week, the month change is a +9.25% rise, over the last year Verrica Pharmaceuticals has showed a -22.39% decrease.
What is Verrica Pharmaceuticals market cap?▼
Today Verrica Pharmaceuticals has the market capitalization of 107.54M
When is the next Verrica Pharmaceuticals earnings date?▼
Verrica Pharmaceuticals is going to release the next earnings report on August 11, 2026.
What were Verrica Pharmaceuticals earnings last quarter?▼
VRCA earnings for the last quarter are -0.45 USD per share, whereas the estimation was -0.42 USD resulting in a -7.2% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Verrica Pharmaceuticals revenue for the last year?▼
Verrica Pharmaceuticals revenue for the last year amounts to 35.58M USD.
What is Verrica Pharmaceuticals net income for the last year?▼
VRCA net income for the last year is -17.89M USD.
How many employees does Verrica Pharmaceuticals have?▼
As of July 12, 2026, the company has 76 employees.
In which sector is Verrica Pharmaceuticals located?▼
Verrica Pharmaceuticals operates in the Health & Wellness sector.
When did Verrica Pharmaceuticals complete a stock split?▼
The last stock split for Verrica Pharmaceuticals was on July 25, 2025 with a ratio of 1:10.
Where is Verrica Pharmaceuticals headquartered?▼
Verrica Pharmaceuticals is headquartered in West Chester, United States.